Effect of statin therapy on plasma apolipoprotein C-III concentrations: a Systematic Review and Meta-Analysis of Randomized Controlled Trials
Articolo
Data di Pubblicazione:
2018
Citazione:
Effect of statin therapy on plasma apolipoprotein C-III concentrations: a Systematic Review and Meta-Analysis of Randomized Controlled Trials / S. Amirhossein, S. Luis E., M. Dimitri P., P. Matteo, B. Maciej, S. Cesare R., M. Ruscica, R. Željko. - In: JOURNAL OF CLINICAL LIPIDOLOGY. - ISSN 1933-2874. - 12:3(2018), pp. 801-809. [10.1016/j.jacl.2018.01.008]
Abstract:
Background
Statins are well established LDL-cholesterol-lowering drugs. Elevated Apo CIII levels are associated with elevated triglyceride-rich particles which are also considered to be a possible risk factor for CVD.
Objective
The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of statins on Apo CIII concentrations.
Methods
Randomized placebo-controlled trials investigating the impact of statin treatment on cholesterol lowering that include lipoprotein measurement were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases (up to July 31, 2017). A random-effects model and generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. A weighted random-effects meta-regression was performed to evaluate the impact of potential confounders on Apo CIII concentrations.
Results
This meta-analysis of data from 6 randomized placebo-controlled clinical trials (10 statin arms) involving 802 subjects showed that statin therapy significantly decreased circulating Apo CIII concentrations (weighted mean difference [WMD]: -2.71, 95% CI: -3.74, -1.68, p<0.001; I2: 73.83%). The effect size was robust in the leave-one-out sensitivity analysis and not driven by any single study. Subgroup analysis showed a reduction of Apo CIII concentrations by atorvastatin (WMD: -4.74, 95% CI: -3.74, -1.68, p=0.002; I2: 84.02%), rosuvastatin (WMD: -2.68, 95% CI: -4.52, -0.84, p=0.004; I2: 0%) and lovastatin (WMD: -1.64, 95% CI: -2.22, -1.07, p<0.001; I2: 0%).
Conclusion
This meta-analysis suggests that statin treatment significantly reduces plasma Apo CIII levels.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
apolipoprotein CIII; statins; cardiovascular disease; atorvastatin; rosuvastatin; lovastatin
Elenco autori:
S. Amirhossein, S. Luis E., M. Dimitri P., P. Matteo, B. Maciej, S. Cesare R., M. Ruscica, R. Željko
Link alla scheda completa: